Intelligence · Clinical Development
Pipeline search results
Programs matching “antibody” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 75 pipeline programs matching "antibody" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Bispecific antibody-based combined with CAR-T cell therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Non-Hodgkin Lymphoma
1 trial -
CD25 antibody combined glucocorticoid as first-line treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Graft Versus Host Disease
1 trial -
CLNP023R12201
Novartis Pharmaceuticals
active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis
1 trial -
CRB-601 monoclonal antibody
Corbus Pharmaceuticals Holdings
Solid Tumor
1 trial -
Cizutamig
Lacuna Pharma Pty Ltd
Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)
1 trial -
EGFR Antibody
The First People's Hospital of Lianyungang
Nasopharyngeal Cancinoma (NPC)
1 trial -
Fostamatinib 150 mg bid
RIGEL PHARMACEUTICALS INC
Warm Antibody Autoimmune Hemolytic Anemia
1 trial -
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Jasper Therapeutics
SCID
1 trial -
INBRX-106 - Hexavalent OX40 agonist antibody
Inhibrx Biosciences
Solid Tumor
1 trial -
Injection of humanized nerve growth factor (NGF) antibody
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Cancer Pain
1 trial -
LM-108 antibody and sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
NK cell and PD-1 antibody
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation
The First People's Hospital of Lianyungang
Locally Advanced Perihilar Cholangiocarcinoma
1 trial -
PD-1 antibody Sintilimab
The First People's Hospital of Lianyungang
Multiple Primary Lung Cancers
1 trial -
PD-1/CTLA-4 Dual Functional Antibody
The First People's Hospital of Lianyungang
Bile Duct Carcinoma
1 trial -
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Psoriasis
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gout Arthritis
1 trial -
Recombinant anti-PD-1 humanized monoclonal antibody injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Sarcoma, Soft Tissue
1 trial -
Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anti-PD-1 Antibody
1 trial -
TNFα Monoclonal Antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Spinal Cord Injuries
1 trial -
Tarperprumig Placebo, Tarperprumig
Alexion Europe SAS
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
1 trial -
Vialed Saline Placebo, ALXN2030
Alexion Europe SAS
Antibody-Mediated Rejection after Kidney Transplantation
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.